Parathyroid Hormone Treatment Increases Fixation of Orthopedic Implants with Gap Healing: A Biomechanical and Histomorphometric Canine Study of Porous Coated Titanium Alloy Implants in Cancellous Bone by Daugaard, Henrik et al.
ORIGINAL RESEARCH
Parathyroid Hormone Treatment Increases Fixation
of Orthopedic Implants with Gap Healing: A Biomechanical
and Histomorphometric Canine Study of Porous Coated Titanium
Alloy Implants in Cancellous Bone
Henrik Daugaard • Brian Elmengaard •
Troels Andreassen • Joan Bechtold •
Anders Lamberg • Kjeld Soballe
Received: 17 April 2010/Accepted: 18 November 2010/Published online: 21 January 2011
 The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract Parathyroid hormone (PTH) administered
intermittently is a bone-building peptide. In joint replace-
ments, implants are unavoidably surrounded by gaps
despite meticulous surgical technique and osseointegration
is challenging. We examined the effect of human
PTH(1–34) on implant ﬁxation in an experimental gap
model. We inserted cylindrical (10 9 6 mm) porous
coated titanium alloy implants in a concentric 1-mm gap in
normal cancellous bone of proximal tibia in 20 canines.
Animals were randomized to treatment with PTH(1–34)
5 lg/kg daily. After 4 weeks, ﬁxation was evaluated by
histomorphometry and push-out test. Bone volume was
increased signiﬁcantly in the gap. In the outer gap
(500 lm), the bone volume fraction median (interquartile
range) was 27% (20–37%) for PTH and 10% (6–14%) for
control. In the inner gap, the bone volume fraction was
33% (26–36%) for PTH and 13% (11–18%) for control. At
the implant interface, the bone fraction improved with 16%
(11–20%) for PTH and 10% (7–12%) (P = 0.07) for con-
trol. Mechanical implant ﬁxation was improved for
implants exposed to PTH. For PTH, median (interquartile
range) shear stiffness was signiﬁcantly higher (PTH 17.4
[12.7–39.7] MPa/mm and control 8.8 [3.3–12.4] MPa/mm)
(P\0.05). Energy absorption was signiﬁcantly enhanced
for PTH (PTH 781 [595–1,198.5] J/m
2 and control 470
[189–596] J/m
2). Increased shear strength was observed
but was not signiﬁcant (PTH 3.0 [2.6–4.9] and control 2.0
[0.9–3.0] MPa) (P = 0.08). Results show that PTH has a
positive effect on implant ﬁxation in regions where gaps
exist in the surrounding bone. With further studies, PTH
may potentially be used clinically to enhance tissue inte-
gration in these challenging environments.
Keywords Parathyroid hormone  Prostheses and
implants  Canine  Biomechanics  Histomorphometry
Introduction
Long-term survival of uncemented total joint replacements
relies on initial mechanical stability, early osseointegration,
and peri-implant bone [1, 2]. Implants are designed to have
stability through exact- or press-ﬁt insertion in cancellous
bone. However, due to individual bone variation and
rasping, gaps unavoidably occur along the length of the
prosthesis at the time of insertion. Lasting secure ﬁxation
requires additional new bone formation, rapidly bridging
the peri-implant gaps and new bone within the porosity of
the implant surface, besides interfacial bone–implant
attachment. Rapid bone growth protects the bone–implant
interface against subsequent ﬂuid pressure with wear-par-
ticle osteolysis and ﬁbrous encapsulation.
Postoperative administration of parathyroid hormone
(PTH) may potentially stimulate gap healing and increase
early implant ﬁxation. PTH has been shown to have an
anabolic effect on bone when administered intermittently.
The effect is an increase in osteoblast number and activity,
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[3–9]. Fracture studies show that PTH augments fracture
healing [10–14]. Some studies have investigated the effect
of PTH on various types of implant ﬁxation. These com-
prise rodent models with insertion in pathological bone [15–
18] or transcortical implantation in normal bone [19–27].
The general ﬁndings are improved bone incorporation. No
studies are available about the effects of PTH treatment on
peri-implant gap healing in normal cancellous bone.
In a parallel 4-week canine study we determined the
effect of PTH on early ﬁxation of titanium implants
inserted press-ﬁt without peri-implant bone defects in
cancellous bone [28]. Systemic PTH(1–34) improved new
bone formation but did not increase mechanical ﬁxation.
Given the clinical prevalence in joint replacement of gaps
surrounding meticulously inserted press-ﬁt implants, it is of
interest to evaluate the effect of PTH on implant osseoin-
tegration in a more challenging environment where the
implant is surrounded by a gap.
We test the hypothesis that PTH(1–34) increases early
bone–implant contact (BIC), peri-implant bone volume,
and mechanical ﬁxation of implants inserted in a gap in
normal cancellous bone.
Materials and Methods
Study Design
The experimental study was performed in 20 canines. A
porous coated gap–implant device was inserted in the
extra-articular metaphyseal cancellous bone of the right
proximal tibia in a 1-mm gap (Fig. 1). Animals were ran-
domized postoperatively to either systemic PTH or control,
and the observation period was 4 weeks.
Test Animal
Our institution’s Animal Care and Use Committee
approved the study. Twenty male American hound dogs
(HRP Covance Research Products, Kalamazoo, MI) were
purpose-bred for research, skeletally mature (veriﬁed
radiographically), with an age mean (range) of 13.8
(11.6–20.0) months and a weight mean (range) of 24.8
(21.0–28.9) kg. Animals were housed individually but
socialized in groups with 1–2 hours of daily exercise.
Hormone Administration
PTH and drug vehicle were prepared in a sterile environ-
ment using a vehicle of heat-inactivated (56C, 1 h) 2%
canine serum (S-1757; Sigma-Aldrich, St. Louis, MO) in
0.9% NaCl adjusted to pH 5. The drugs for the whole study
were prepared all at once and stored at -20C. The
intervention group was injected with human PTH(1–34)
(research grade; Bachem Holding, Bubendorf, Switzerland)
subcutaneously 5 lg/kg body weight adjusted to body
weight weekly. Injections were daily (with the exception of
one day) between 8:00 and 10:00 a.m. starting the day after
surgery with postoperative randomization. On day 11
PTH(1–34) was changed from research grade to GMP
grade (Bachem, Torrance, CA) with unaltered dosage due
to concern over triﬂuoroacetic acid (TFA) content. The
control group was injected with the equivalent volume of
drug vehicle. Total serum calcium was collected twice in
the observation period. Other unrelated studies on PTH
treatment in other implant environments were conducted at
other bone sites in this set of test animals.
Implants
Cylindrical, plasma-sprayed, porous coated titanium alloy
implants (Ti6Al4V ELI, ASTM F136; Biomet, Warsaw, IN)
were inserted in a 1-mm circumferential gap (Fig. 1).
Implants were custom-made, cylindrical, with a porous coat
surface of plasma-sprayed titanium alloy (Ti6Al4V ELI,
ASTM F136) superimposed on an implant core of similar
titanium composition. The coating process by the manu-
facturer is the same in both the manufacturer’s clinical
implant and the experimental implants. The coatings are
considered equal. The nominal diameter was 6 mm (mean
Fig. 1 Gap-implant device inserted in proximal tibia in a 1-mm gap.
Implant diameter 6 mm, length 10 mm, end washer 8 mm. Porous
coat of plasmaspray titanium alloy (Ti6Al4 V)
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123[SD] 6.2 [0.06] mm) and the length was 10 mm. An end-cap
with a nominal diameter of 8 mm centralized the implant in
the implant bed. Implants were cleaned in an ultrasonic bath
of trichlorethylene with ﬁnal baths of alcohol and then
autoclave-sterilized. A surface topographic analysis was
carried out on four randomly chosen implants (Somicronic
Surfascan 3CS; Hommel Somicronic, Saint-Andre ´-de-Corcy,
France) (Danish Technological Institute, Copenhagen,
Denmark). The implant roughness was mean (range) Ra
(arithmetic average of the deviation from the mean line over
a sampling length) = 66.1 (60.7–72.8) lm, Rz (average
height difference between the ﬁve highest peaks and the ﬁve
lowest valleys) = 307.1 (290.4–323.3) lm, Rq (root mean
squarevalueoftheproﬁledeparture)=79.0(72.8–85.5)lm,
and Rmax (maximum peak-to-valley height) = 307.1
(290.4–323.3) lm.
Surgery
Surgery was performed under sterile conditions and under
general anesthesia. Premedication included atrophine 0.4
mg/ml 1 ml/4.5 kg s.c. and acepromazine 10 mg/ml 0.1 ml/
4.5 kg s.c. Anesthesia was covered by thiopental 5% 8 ml
i.v. prior to intubation and maintenance by inhalation iso-
ﬂurane 1.5%. Postoperative pain management consisted of
wound inﬁltration with bupivacaine 2.5 mg/ml 2 ml and
intramuscular injections of bupronex (buprenorphine)
0.3 mg/ml 0.01 mg/kg daily for 3 days. Prophylactic anti-
biotic rocephone (ceftriaxone) was administered preoper-
atively 1 g i.v. and for the ﬁrst 3 days 1 g i.v./day.
The anteromedial surface of the proximal tibia was
exposed by a medial incision sparing the medial collateral
ligament. The periosteum was elevated and a 2.5-mm
guidewire inserted into the proximal tibial metaphyseal
bone 12 mm from the femoral–tibial joint line, perpen-
dicular to the anterior medial bone surface. An 8.0-mm
cannulated drill prepared the cylindrical bone cavity, with
speed less than two revolutions per second and cooling
with saline irrigation drip. Immediately after drilling, the
implant was inserted and solid ﬁxation was obtained. The
overlying soft tissue was closed in layers. Postoperatively,
the canines were allowed unrestricted weight bearing.
X-rays were obtained to conﬁrm correct implant position.
The same surgeon inserted all implants.
Specimen Preparation
Bacterial cultures were taken at removal of bones with
implants in situ, and bone specimens were frozen at -20C
until sectioning. Specimen preparation was done in a
blinded fashion as to treatment group. Two transverse
bone-implant specimens were obtained using a water-
cooled diamond band saw and implant-based alignment
post (Exact Apperatebau, Nordstedt, Germany) (Fig. 2).
The ﬁrst and most superﬁcial specimen with a thickness of
3.5 mm was used for mechanical testing and stored at
-20C. The inner 6.5-mm implant section was ﬁxed in
alcohol 70% and prepared for undecalciﬁed histomorpho-
metric evaluation with implant in situ.
Histological Analysis
Specimens were dehydrated in graded ethanol (range
70–100%) containing 0.4% basic fuchsine (Merck, Darms-
tadt, Germany) followed by embedding in methylmethac-
rylate (MMA; Merck, Hohenbruun, Germany). The
specimen bloc was randomly rotated around its long axis,
and four vertical uniform random sections were cut with a
hard tissue microtome (KDG-95; MeProTech, Heerhugo-
ward, the Netherlands) [29]. These techniques have been
shown to provide reliable results with minimal bias [30].
Sections were cut serially at the center part of the implant,
parallel to the implant’s long axis, and 400 lm apart as the
space minimally achieved due to the kerf of the saw. The
thickness mean (SD) was 40.8 (7.1) lm. The surface was
counterstained with 2% light green (Light Green SF; BDH
Laboratory Supplies, Poole, UK) for 2 min [31]. The stain-
ing technique distinguishes bone at the specimen surface
(green) and ﬁbrous tissue/marrow-like tissue (red). The
penetration depth of the light green stain has been deter-
mined to be in the range of 4–10 lm[ 32], enabling deter-
mination of the superﬁcial morphological focus plane for
histomorphometric tissue sampling.
Static histomorphometry quantiﬁed tissue ongrowth at
the implant surface (percentage coverage of implant sur-
face) and peri-implant tissue volume (volume percentage).
Analysis was performed blinded in random specimen order
with a light microscope (Olympus BX51 TF; Olympus
Optical, Tokyo, Japan) and a computer-assisted stereo-
logic image analysis system (Cast, version 2.1.4; Olympus,
Albertslund, Denmark).
Regions of the 1 mm gap were deﬁned along the whole
section as an outer gap region of 500 lm, an inner gap
region reaching the implant, and a 1,000-lm circumferen-
tial region of the host bone not subjected to implantation
(Fig. 3). Tissue ongrowth was deﬁned as tissue directly at
the implant surface and estimated by the line intercept
technique with randomly disposed sine-weighted lines.
Peri-implant tissue volume was estimated using point
counting with randomly disposed points. The test system
was calibrated with a minimum of 100 line interceptions
and points for the tissue of interest in each region. Sampling
was done by the meander method. Each zone was evaluated
separately during a specimen sampling session. The speci-
men preparation, stereologic software, and systematic uni-
form random sampling made it possible to obtain unbiased
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123estimates, although anisotropy of cancellous bone exists
[29, 33]. All implant-related measurements were done by
the same person (primary author H. D.). For comparisons of
intact bone, measurements were completed by an experi-
enced histomorphometry technician (J. P.). Reproducibility
was deﬁned by determination in duplicate by the same
person (H. D.) of two PTH and two control implants (16
specimens) randomly selected. The coefﬁcients of variation
for bone were 2 and 6% in the outer/inner gap regions and
7% at the implant interface.
Mechanical Testing
Implants were tested to failure by axial push-out test (MTS
858 Mini Bionix, Software MTS Test Star 790.00, version
4.00; MTS System, Minneapolis, MN). Testing was done
blinded and all in one session. Push-out was done from the
external side of the bone inward. Specimens were placed on
a metal support jig with a 7.4-mm-diameter circular central
opening, leaving a 0.7-mm distance between the implant
and support jig as recommended by Dhert et al. [34]. A
preload of 2 N deﬁned the standardized contact position for
starting the test. A standard displacement velocity of 5 mm/
minute was used. Continuous load-displacement data were
recorded, obtaining maximum shear stiffness (slope of the
linear section of the load vs. displacement curve), ultimate
shear strength (maximum force applied until failure of the
bone-implant interface), and total energy absorption (area
under the load-displacement curve until failure). All push-
out parameters were normalized by the cylindrical surface
area of the implant. Determining the reproducibility of the
push-out test was not possible due to its destructive nature.
Statistical Analysis
STATA statistical software (Stata 10.1; StataCorp, College
Station, TX) was used. Because data were not normally
distributed, statistical analysis was the nonparametric two-
sample Wilcoxon rank-sum (Mann–Whitney) test with
assessment of the difference between treatment groups.
Estimates are given as medians and interquartile ranges,
and two-tailed P values\0.05 are considered statistically
signiﬁcant. The sample size was based on a sample size
estimation, which was carried out prior to the study based
on previous studies at our institution in this implant model.
Results
Surgery
The day after surgery all animals were fully weight-bear-
ing. Two animals in the PTH group died on days 6 and 8
postoperatively. Autopsy revealed ventricular hypertrophy
and myositis in both. All other animals completed the
observation period with no abnormal serum calcium levels.
6,5
6,5 3,5
3,5
Fig. 2 Sectioning technique.
Implant in situ tibial
metaphyseal bone. Outer
Section 3.5 mm for mechanical
testing, inner Section 6.5 mm
for histomorphometry
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123No other complications and no signs of infection in the
implant sites were observed. All bacterial cultures taken at
the time of death were negative.
Histology
A qualitative histological examination revealed that bone
in the gap in the PTH group consisted of abundant
immature bone with no speciﬁc orientation of trabeculae
forming a ﬁne-meshed bone web (Fig. 4). Trabeculae were
thicker and more numerous and had improved connectivity
compared to the control group. In PTH specimens trabec-
ulae were more abundant but appeared thinner in the gap
region compared to the region of intact host bone. Fibrous
tissue was observed in six PTH implants and ﬁve controls
and located at the bone–implant interface.
Histomorphometry
PTH caused a signiﬁcant increase in new bone in the 1-mm
peri-implant gap (Table 1). In the outer half of the gap a
2.5-fold median increase was seen, and similarly a 2.4-fold
increase was seen in the inner part. At the interface, PTH
increased bone contact nonsigniﬁcantly by a median of
1.6-fold (P = 0.07). Fibrous tissue was only observed in
the inner gap, and no signiﬁcant differences were seen in
the gap or at the interface between the PTH and control
groups. No differences in bone or ﬁbrous tissue were
observed in the 1,000-lm remaining peri-implant region of
the host bone not subjected to implantation.
Mechanical Testing
Results of the mechanical testing are summarized in Fig. 5.
One mechanical implant specimen was excluded during
mechanical testing due to oblique placement on the support
jig. Randomization code post hoc revealed the implant to
be in the control group. PTH signiﬁcantly increased shear
stiffness 2-fold, with a median (interquartile range) of PTH
17.4 (12.7–39.7) MPa/mm and control 8.8 (3.3–12.4)
MPa/mm. Energy absorption was signiﬁcantly 1.7-fold
higher, with a median (interquartile range) of PTH 781
(595–1,198) J/m
2 and control 470 (189–596) J/m
2. Shear
strength demonstrated a nonsigniﬁcant 1.5-fold increase
with PTH 3.0 (2.6–4.9) MPa and control 2.0 (0.9–3.0) MPa
(P = 0.08).
Discussion
The purpose of this study was to determine whether
intermittent systemic PTH(1–34) had an effect on the early
ﬁxation of implants inserted in a gap in cancellous bone.
We found a signiﬁcant increase in bone volume in both the
inner and outer parts of the 1-mm gap. Increased bone
contact with the implant surface was observed but was not
signiﬁcant. No bone volume enhancement was seen in the
region of intact nonimplanted bone surrounding the
implant. PTH increased signiﬁcantly the mechanical
implant ﬁxation in shear stiffness and energy absorption.
We used an established experimental model designed to
represent a cementless human joint replacement prosthesis
surrounded by cancellous bone. The implant was inserted
in a well-deﬁned gap of normal nonpathological bone and
was porous coated with the same technique as for the
clinical applications of the manufacturer’s prostheses. The
model was nonarticular and not directly weight bearing,
which partly omits the effect of the mechanical stimuli on
bone formation alone or as a PTH enhancement [35]. Based
on previous implant studies, the gap size of 1 mm is suf-
ﬁcient to delay or prevent substantial healing without
intervention during a 4-week observation period [36]. Also,
abundant cancellous bone in this test animal limits inter-
ference of a cortical envelope in contributing to implant
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Fig. 3 Histomorphometry. Region of interest (ROI) is on both
implant sides and illustrated on one side above. Tissue ongrowth at
interface. Tissue volume in gap of 1 mm divided in two of an in inner
gap region and an outer gap region (500 lm). Tissue volume in region
of intact nonimplanted bone (1,000 lm). Regions deﬁned from
washer margins as a ﬁxed point with a 100-lm clearance at gap-intact
bone interface and 400 lm below washer. ROI deﬁnition objective/
total magniﬁcation 91.25/954, data sample at 910/9431
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interindividual biological variation in bone structure. When
initiating new treatments for human joint replacements, it
is crucial that evaluation is done in clinically relevant
animal and bone models. It is known that the magnitude of
bone anabolic response to intermittent PTH depends on
species, bone sites, and bone envelopes [6, 7, 37–39]. PTH
has not previously been evaluated in this canine model.
The canine bone structure most closely resembles human
bone and the sites for implantation [40–42]. The native
PTH(1–84) and PTH(1–34) fragments show equivalent
biological activities at equimolar concentrations [43].
However, the bone anabolic window of PTH is both dose-
and time-dependent [10, 13, 19]. We chose a single dose of
PTH(1–34) 5 lg/kg body weight with dosage within the
range studied with other animal models and relevant as to
this animal species [3, 7, 44–46]. The systemic nature of
PTH administration required an unpaired study design. A
low concentration of TFA is present in research-grade
PTH. After two test animals died, as a precaution we
changed PTH to GMP grade from day 11 with the same
dosage (Bachem Certiﬁcate of Analysis). For the remaining
observation period the animals were closely monitored, and
all completed the course uneventfully.
The osseointegration of an implant may be considered as
a cancellous bone healing process bridging peri-implant
gaps. With a titanium alloy implant being bioinert, con-
ventional gap healing is by unidirectional intramembranous
ossiﬁcation encircling the implant [36]. With intermittent
Fig. 4 Histology.
Photomicrographs of
representative histological
samples. a, b Control sample.
c, d PTH sample.
a, c Magniﬁcation 945,
bar = 1,000 lm.
b, d Magniﬁcation 9160,
bar = 500 lm. Staining
technique 0.4% basic fuchsin
(red) and 2% light green
(green = bone). PTH shows
increase in bone in the gap with
no speciﬁc orientation of
trabeculae. The intact bone
outside the gap is visible
(Color ﬁgure online)
Table 1 Histomorphometry
Bone Marrow Fibrous
Interface
Control 10 (7–12) 77 (70–88) 8 (0–21)
PTH 16 (11–20)
1) 74 (56–80) 7 (0–35)
Inner gap
Control 13 (11–18) 82 (77–85) 2 (0–7)
PTH 33 (26–36)*** 60 (53–69)** 3 (0–14)
Outer gap
Control 10 (6–14) 90 (86–94) 0 (0–0)
PTH 27 (20–37)** 73 (63–80)** 0 (0–0)
Intact bone
Control 22 (19–23) 78 (77–81) 0 (0–0)
PTH 22 (18–30) 78 (70–82) 0 (0–0)
Implant inserted in concentric gap 1 mm in cancellous bone. PTH
treatment versus control. Bone, marrow-like and ﬁbrous tissue at
implant surface (surface fraction), concentric region divided in two of
inner gap, outer gap (500 lm), and intact bone outside the gap
(1,000 lm) (volume fraction). PTH n = 8, control n = 10. Mann–
Whitney test, median, interquartile range, ** P\0.01, *** P\
0.001,
1) P = 0.07, PTH compared to control within region
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123PTH treatment, the fundamental anabolic mechanism is
more complex. The PTH-enhanced regenerative process in
fracture healing may differ from the gap healing of a bone–
material interface. PTH increases osteoblast number and
activity [47] by recruiting osteoprogenitor cells [6] and
transforming resting bone lining cells [5, 6]. PTH also
stimulates chondrogenesis by recruitment of chondropro-
genitor cells [48]. Bone formation of PTH(1–34) has been
evaluated by placing bone conduction chambers in endos-
teal bone of rat tibia [49] and rabbit mandible [50]. Skripitz
et al. [49] found from weeks 2 to 6 a small and nonsig-
niﬁcant increase in ingrowth distances of bone into the
chamber, a metaplastic (membranous) ossiﬁcation, and
with time a ﬁvefold increase in bone density within the
bone chamber. In nonimplanted remodeling bone in the
same rats an increase in density was barely detectable. In
our study new bone had already extended homogenously
into the entire gap in the PTH group and no signiﬁcant
differences were seen in bone volume between the inner
and outer gap regions. Given the 4-week observation per-
iod in a 1-mm gap, discrimination is not possible between
an ossiﬁcation process of an osteoconductive ossiﬁcation
frontline progressively expanding unidirectionally or a
contribution of osteoinductive ossiﬁcation inlets scattered
in the gap expanding multidirectionally. PTH may show
potency in initial healing of even larger peri-implant
defects.
The data indicate that PTH could be used clinically. We
found PTH treatment to increase peri-implant gap bone
volume (P\0.01). The BIC increase was not signiﬁcant
(P = 0.07), while there was an unaltered amount of bone in
the surrounding intact bone region. The mechanical resis-
tance of an implant relies on the amount of bone adjacent to
the implant, its quality, and its trabecular architecture. PTH
increased early mechanical ﬁxation in shear stiffness and
energy absorption. The increase in shear strength was
nonsigniﬁcant (P = 0.08) and may be subscribed to BIC
with the near-signiﬁcant improvement in bone interlocking
statically to the implant surface. Also, the time interval
observed, the level of bone maturation, and the loss of a test
animal in the PTH group may be taken into consideration.
With respect to the inﬂuence of PTH on bone regeneration,
Andreassen et al. [10] reported that in normal adult rats 60
and 200 lg/kg daily PTH(1–34) increased the amount of
callus and mechanical strength of fractures after 40 days of
healing. Proportionate ﬁndings are documented in other
studies with PTH(1–34) and PTH(1–84) in rats [11, 12, 51],
larger animals [13], and recently in humans [14]. No pre-
vious study has determined the effect of gap healing with
PTH(1–34) on implants inserted in a deﬁned bone defect
with normal cancelleous bone of human characteristics.
Instead, ﬁxation of prostheses by adjuvant PTH adminis-
tration has so far been conﬁned to rodents in situations of
screws implanted transcortically with part of the screw
being in cortical bone [18–21, 23, 24, 26, 27] or of rods in
bone with pathological low bone density [15–17, 52]. The
general ﬁndings in these interference ﬁt rodent models are
improved incorporation in bone. In ovariectomized rats,
administering PTH(1–34) 5, 25, or 75 lg/kg daily for
8 weeks increased mechanical pull-out force, stiffness, and
toughness of conical titanium screws. Osseointegration and
0
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Fig. 5 Mechanical testing push-out-to-failure. Box plot, median,
quartiles, sample range. Maximum shear stiffness, maximum shear
strength, and total energy absorption. Control n = 9, PTH n = 8.
Mann–Whitney test *P\0.05,
1)P = 0.08, PTH compared to control
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123bone volume were increased with no difference between the
highest doses [15]. PTH(1–34), 25 lg/kg ﬁve times weekly,
rescued the peri-implant bone volume and mechanical
function by augmenting trabecular thickness [23].
PTH(1–34), 60 lg/kg three times a week, increased the
pull-out strength of screws implanted transcortically in
normal bone of rats at 2 and 4 weeks and implant bone
contact at 1, 2, and 4 weeks [21]. We determined in a par-
allel 4-week canine study that systemic PTH(1–34) 5 ug/kg
daily does not improve the early implant ﬁxation of porous
coated titanium alloy implants inserted press-ﬁt [28].
Stimulating new bone formation at the bone-implant inter-
face did not improve the overall mechanical resistance to
push-out. Using a test-animal model of clinical relevance
with comparable bone quality and implanted cancellous
bone envelope, press-ﬁt implants showed moderate
improvement with PTH. In the present study inserting
implants in a situation of peri-implant bone defects initiates
a regenerative process of bone repair in the gap, which is
signiﬁcantly improved by PTH.
Conclusion
Intermittent treatment with PTH enhances early ﬁxation of
orthopedic implants surrounded by a gap in terms of
increased bone in the gap and increased mechanical sta-
bility. Treatment with PTH exerts its bone-stimulatory
effect locally around the implant when administered for a
short period, with no observed general bone effect. These
ﬁndings suggest that in joint replacements adjuvant PTH
may be useful in improving healing of the inevitable peri-
implant bone defects. Further studies are needed with
respect to the short-term effects of PTH, on time and dose
dependence, in critical gap size, and other implant settings,
as well as long-term changes in bone in the gap after
cessation of PTH administration.
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